Haemonetics Study Validates Faster, Safer Cardiac Procedure Recovery

BOSTON, MA – August 03, 2026

A new large-scale study is providing a clearer picture of the future of cardiac care, and it’s one where patients go home sooner and safer. Haemonetics Corporation (NYSE: HAE) today confirmed the publication of a landmark study from Emory University, validating the performance of its VASCADE MVP® XL vascular closure system. The real-world data demonstrates that the device not only seals large-bore venous access points in minutes but also enables over 90% of patients undergoing complex electrophysiology procedures to be discharged the very same day. For a field rapidly advancing with powerful new therapies, this innovation in a supporting technology is proving to be a critical enabler of progress, streamlining hospital workflows and fundamentally improving the patient experience.

The findings come at a pivotal moment. The rise of sophisticated treatments for conditions like Atrial Fibrillation (AF) and stroke prevention, such as Pulsed Field Ablation (PFA) and Left Atrial Appendage Closure (LAAC), has been a game-changer. However, these procedures require larger instruments and, consequently, larger access points in the femoral vein. Managing these "large-bore" sites post-procedure has been a persistent clinical challenge, often requiring long periods of manual pressure and overnight hospital stays to prevent bleeding complications. This new evidence suggests that Haemonetics may have unlocked a key to solving that bottleneck.

Redefining the Standard of Post-Procedural Care

The single-center retrospective study, conducted at Emory University with a grant from Haemonetics, is the largest of its kind, analyzing outcomes from 1,623 patients. The results are striking: the VASCADE MVP XL system achieved hemostasis—the cessation of bleeding—in a median time of just two minutes. This efficiency translated directly into a 92.5% same-day discharge rate, with patients leaving the hospital in a median of 3.5 hours. Crucially, this was achieved with a strong safety profile, showing only a 1.2% rate of overall vascular complications and no instances requiring surgical intervention.

"What is particularly notable is that same-day discharge was consistently achieved, even with sheaths larger than historically used in device-based closure," noted the study's corresponding author, Dr. David B. De Lurgio, Medical Director of Electrophysiology at Emory Saint Joseph's Hospital. He emphasized the breadth of the data, stating, "With more than 1,600 patients in this cohort, the findings provide additional real-world evidence across a broad range of patients and procedures, including those with higher comorbidities in LAAC and concomitant cases."

This performance is significant because the VASCADE MVP XL is the only extravascular venous closure system clinically proven for use with the large procedural sheaths (up to 17F outer diameter) that are becoming the norm. Its design, featuring a resorbable collagen patch delivered outside the vessel, effectively plugs the access site without leaving an implant inside the vein. This approach directly challenges the traditional method of prolonged manual compression, which is not only resource-intensive for hospitals but also deeply uncomfortable for patients, requiring them to lie immobile for hours.

A Strategic Move in a Crowded Field

While the clinical benefits are clear, the announcement is also a calculated strategic move by Haemonetics to solidify its position in the competitive vascular closure device (VCD) market, a sector projected to exceed $2.5 billion by 2033. The company faces formidable competitors, including Abbott with its suture-based Perclose ProGlide system and Teleflex with its collagen-plug MANTA device. However, Haemonetics is carving out a defensible niche by aligning its technology squarely with the needs of the booming electrophysiology (EP) space.

In March 2026, the company secured expanded FDA labeling for the VASCADE MVP XL, officially approving its use with the market-leading PFA and LAAC systems from giants like Boston Scientific (FARAPULSE®, WATCHMAN TruSteer®), Medtronic (Sphere-9® catheter), and Abbott (Volt® PFA System). This regulatory green light, supported by the prior AMBULATE EXPAND clinical trial, effectively makes the VASCADE MVP XL an essential companion technology for the most advanced cardiac procedures available today.

"As physicians seek innovative closure technologies to help improve clinical outcomes and patient experiences across PFA, LAAC and concomitant procedures, VASCADE MVP XL is providing electrophysiology teams with a safe, reliable and effective solution," said Ken Crowley, Vice President and General Manager of Interventional Technologies at Haemonetics.

This focus on the EP lab is further underscored by the company's recent acquisition of Vivasure Medical, a firm specializing in fully bioresorbable large-bore closure devices for structural heart procedures. Together, these moves signal a clear intent by Haemonetics to dominate the large-bore closure segment by offering a specialized, evidence-backed portfolio that its more generalized competitors may struggle to match. By proving its device works seamlessly with the next generation of therapeutic catheters, Haemonetics is embedding itself into the procedural ecosystem.

The Patient Journey: A Faster Path to Recovery

Beyond market dynamics and clinical statistics, the most profound impact of this technology is on the patient. For individuals undergoing life-altering cardiac procedures, the recovery process is as important as the intervention itself. The ability to ambulate within hours and return home the same day is not merely a convenience; it is a significant improvement in quality of life that reduces hospital-acquired risks and eases psychological stress.

"For the patient, this is the difference between an overnight hospital stay with restricted movement and being home with their family the same evening," commented one independent electrophysiologist not involved in the study. "It's a massive leap forward in patient-centered care and hospital efficiency. When we can reliably close these large access sites and get patients on their feet quickly, it transforms the entire care pathway."

This efficiency generates a powerful ripple effect across the healthcare system. By facilitating same-day discharge, hospitals can improve patient throughput, optimize bed utilization, and lower the overall cost of care. In an era of increasing pressure on healthcare resources, technologies that enhance both clinical outcomes and operational efficiency are positioned for widespread adoption.

The publication of the Emory study provides the real-world validation needed to accelerate this adoption. While retrospective and industry-funded studies warrant careful scrutiny, a dataset of this magnitude from a high-volume, experienced center provides a compelling case for the technology's reliability. It builds upon a foundation of prospective data and regulatory approval, creating a robust body of evidence. As the field of interventional cardiology continues to innovate, the enabling technologies that support these breakthroughs are proving to be just as critical as the primary treatments themselves, ensuring that progress is measured not just in procedural success, but in a patient's swift and safe return to a full life.